This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

63/100

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Importance It remains unclear which risk factors accelerate brain atrophy along with a progression from normal cognition to mild cognitive impairment (MCI). Objective To examine risk factors associated with the acceleration of brain atrophy and progression from normal cognition to MCI based on long-term longitudinal data for middle-aged and older adults. Design, setting, and participants Data for this cohort study were extracted from the Biomarkers for Older Controls at Risk for Dementia (BIOCARD) cohort, initiated at the National Institutes of Health from January 1, 1995, to December 31, 2005, and continued at Johns Hopkins University from January 1, 2015, to October 31, 2023.

Key findings

Objective To examine risk factors associated with the acceleration of brain atrophy and progression from normal cognition to MCI based on long-term longitudinal data for middle-aged and older adults.
Design, setting, and participants Data for this cohort study were extracted from the Biomarkers for Older Controls at Risk for Dementia (BIOCARD) cohort, initiated at the National Institutes of Health from January 1, 1995, to December 31, 2005, and continued at Johns Hopkins University from January 1, 2015, to October 31, 2023.
All participants were cognitively normal at baseline.
The participants whose structural magnetic brain imaging (MRI) of the brain and cerebrospinal fluid (CSF) measures were available for over 10 years were included.

Why it matters

Using long-term data from middle-aged and older adults, this cohort study examined which risk factors are linked to faster brain atrophy and progression from normal cognition to mild cognitive impairment. It identifies associations over time but does not show that changing these factors prevents progression.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designcohort study
Participants185
Evidence strengthModerate

How this study scored 63/100

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for effect reported and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (JAMA network open)
Journal's citation record	2 / 4	JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29)
Study design	7 / 12	A cohort study following people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2024 — within 3 year(s) of the newest study here
Sample size	2 / 4	185 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	3 / 7	Cited 33 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	8.2 citations a year over 4 year(s) since 2024
Impact for its field and year	4 / 6	Cited 9.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 6 other studies in this library
Still being cited	2 / 4	Cited 33 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Kenichi Oishi: h-index 47 (OpenAlex, whole career)
Institution's track record	2 / 3	Johns Hopkins University: institution h-index 2,306 (OpenAlex)
Multi-centre collaboration	1 / 3	OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 39476236)
Free to read	2 / 2	Free to read
Total	63 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Uchida, Y., Nishimaki, K., Soldan, A., Moghekar, A., Albert, M., & Oishi, K. (2024). Acceleration of Brain Atrophy and Progression From Normal Cognition to Mild Cognitive Impairment. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2024.41505

Vancouver

Uchida Y, Nishimaki K, Soldan A, Moghekar A, Albert M, Oishi K. Acceleration of Brain Atrophy and Progression From Normal Cognition to Mild Cognitive Impairment. JAMA network open. 2024. doi:10.1001/jamanetworkopen.2024.41505. PMID: 39476236.

BibTeX

@article{uchida2024-39476236,
  author  = {Uchida, Y. and Nishimaki, K. and Soldan, A. and Moghekar, A. and Albert, M. and Oishi, K.},
  title   = {{Acceleration of Brain Atrophy and Progression From Normal Cognition to Mild Cognitive Impairment}},
  journal = {JAMA network open},
  year    = {2024},
  doi     = {10.1001/jamanetworkopen.2024.41505},
  pmid    = {39476236},
  url     = {https://doi.org/10.1001/jamanetworkopen.2024.41505}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.

Later studies that cite this one

6 studies in the alzhub library list this one in their references.

Related studies in Tau biomarkers

Also tagged “assessment”

840 studies in the library carry the topic tag “assessment”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →